Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 in Subjects Who Have Completed Study 1001
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Peptide p277 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Andromeda Biotech
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 08 Sep 2014 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2014, according to a Hyperion Therapeutics media release.